Cervical Dysplasia Market, By Diagnosis Type (Diagnosis Test (HPV Test, Pap Smear Test, Biopsy Test) and Diagnostic Device (Colposcope)), By End User (Hospitals, Diagnostic Centers, and Ambulatory Surgery Centers), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
The Cervical Dysplasia Market size is expected to reach US$ 1,105.4 Mn by 2030, from US$ 675 Mn in 2023, exhibiting a compound annual growth rate (CAGR) of 7.3% during the forecast period. Cervical dysplasia is a condition in which abnormal cells grow on the surface of the cervix. Without treatment, cervical dysplasia can lead to cervical cancer. With early detection and treatment, the growth of these abnormal cells can be prevented from becoming cancerous.
Cervical Dysplasia Market Regional Insights:
North America is expected to be the largest market for cervical dysplasia market during the forecast period, accounting for over 40% of the market share in 2022. The growth of the market in North America is due to increasing product launches
The Europe market is expected to be the second-largest market for cervical dysplasia market, accounting for over 27.3% of the market share in 2022. The growth of the market in Europe is due to increasing inorganic strategies by the market players.
The Asia Pacific market is expected to be the fastest-growing market for cervical dysplasia market, with a CAGR of over 9.2% during the forecast period. The growth of the market in Asia Pacific is due to increasing prevalence of hepatitis C in the region.
Figure 1. Cervical Dysplasia Market Share (%), By Region, 2023
Cervical dysplasia market is expected to propel over the forecast period due to increasing prevalence of cervical dysplasia globally and increasing research and development (R&D), and product launches by the market players. Moreover, increasing funding for the research and developmental activities is also expected to boost the market growth over the forecast period.
Cervical Dysplasia Market Drivers:
Growing prevalence of cervical dysplasia globally: Increasing prevalence of cervical dysplasia globally is expected to drive the market growth over the forecast period. For instance, according to the data published by the Springer Nature in August 10, 2023, global prevalence estimation of high-grade cervical dysplasia was 4.3%, and the global prevalence estimate of low-grade cervical dysplasia was 6.2%. The highest prevalence of cervical dysplasia was reported in the European continent.
Increasing government initiatives: Increasing government initiatives and increasing awareness programs will aid in the market growth over the forecast period. For instance, in May 2018, the World Health Organization (WHO) Director-General announced a global call for action to eliminate cervical cancer, In August 2020, the World Health Assembly adopted the global strategy for cervical cancer elimination.
Cervical Dysplasia Market Opportunities:
Increasing government funding: The cervical dysplasia market is experiencing significant growth due to rising government focus and funding towards cervical cancer prevention programs around the world. Various governments are allocating increased healthcare budgets for nationwide screening and vaccination initiatives to curb the rising cervical cancer burden. For example, governments in the U.S., U.K., Australia, and Canada have invested over US$500 Mn cumulatively between 2020-2022 for cervical screening programs and human papillomavirus infection (HPV) vaccination drives according to data published by OECD and WHO.
Cervical Dysplasia Market Report Coverage
Report Coverage
Details
Base Year:
2022
Market Size in 2023:
US$ 675 Mn
Historical Data for:
2018 to 2021
Forecast Period:
2023 - 2030
Forecast Period 2023 to 2030 CAGR:
7.3%
2030 Value Projection:
US$ 1,105.4 Mn
Geographies covered:
North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East & Africa: GCC Countries, Israel, South Africa, North Africa, and Central Africa and Rest of Middle East
Segments covered:
By Diagnosis Type: Diagnosis Test (HPV Test, Pap Smear Test, Biopsy Test) and Diagnostic Device (Colposcope)
By End User: Hospitals, Diagnostic Centers, and Ambulatory Surgery Centers
Companies covered:
Roche, Qiagen, Abbott Laboratories, BD, Hologic, Seegene, Arbor Vita, Femasys, and Cooper Surgical
Increased adoption of HPV vaccination: human papillomavirus infection (HPV)vaccination programs led by governments and health organizations have strengthened over the years. For example, in the U.S.A., HPV vaccination completion rates among eligible adolescents increased from 48.6% in 2017 to 60.5% in 2020, as per reports from center for disease control and prevention (CDC). Similarly, countries like the U.K., Australia, and some European nations have observed vaccination coverage of over 80%, among young females, due to sustained school-based immunization drives. This widespread use of HPV vaccines means fewer girls and women will develop precancerous cervical lesions later in their lives.
Cervical Dysplasia Market Restraints:
Lack of awareness in developing nations: The lack of awareness has profound influence on market potential in developing countries. When women lacks the knowledge that cervical dysplasia can potentially lead to cancer if left undetected and untreated, it sharply reduces the demand for diagnostic tests, diagnostic devices, and precautionary treatments. According to USAID, over 70% of cervical cancer deaths in Africa can be avoided with early detection and treatment. However, the low rates of cervical screening in Africa - averaging below 5% - can be attributed to lack of awareness and misconceptions regarding the disease. This gap between preventable deaths and actual cases treated indicates the significant market opportunity that is being lost due to insufficient community education and health messaging in developing economies.
Counterbalance: The women population in the developing countries must be made aware by providing proper knowledge of cervical dysplasia and its dire consequences which may lead to cervical cancer, if not treated at the right time.
Recent Developments:
New product launches:
In July 13, 2022, Serum Institute of India, a biotechnology company, launched vaccine to prevent cervical cancer.
In June 16, 2022, Roche, a pharmaceutical company, headquartered in Switzerland, launched a human papillomavirus (HPV) self-sampling solution in countries accepting the Conformité Européenne CE mark. This new solution enables a patient to privately collect their own sample for HPV screening.
Acquisition and partnerships:
In March 2019, QIAGEN, a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research and INOVIO, an American biotechnology company focused on the discovery, development, and commercialization of synthetic deoxyribonucleic acid (DNA) products announced a collaboration to develop a companion diagnostic to guide clinical decision-making for the use of INOVIO’s DNA-based immunotherapy to treat cervical dysplasia caused by
Increasing prevalence of cervical dysplasia in women’s is expected to aid in the market growth over the forecast period, moreover increasing product launched and increasing inorganic strategies by the market players will aid in the market growth over the forecast period.
Definition: Cervical dysplasia is a condition in which abnormal cells grow on the surface of the cervix. Without treatment, cervical dysplasia can lead to cervical cancer. With early detection and treatment, the growth of these abnormal cells can be prevented from becoming cancerous.
Share
About Author
Abhijeet Kale is a results-driven management consultant with five years of specialized experience in the biotech and clinical diagnostics sectors. With a strong background in scientific research and business strategy, Abhijeet helps organizations identify potential revenue pockets, and in turn helping clients with market entry strategies. He assists clients in developing robust strategies for navigating FDA and EMA requirements.
U.S.: 
U.K. : 
India : 
